European regulators OK Alzheimer's treatment Leqembi after initial doubts
- The European Commission approved lecanemab to treat Alzheimer's, making it the first therapy to receive a marketing authorization in the EU.
- Lecanemab is the first treatment option in the EU that can slow the progression of early Alzheimer's disease.
- This decision applies to all 27 EU member states and Norway, Iceland, and Liechtenstein.
- Shares of Biogen rose about $2 to $119 in premarket trading following the approval.
131 Articles
131 Articles
Immune-system strategy used to treat cancer may help with Alzheimer’s — Harvard Gazette
Vijay Kuchroo.Veasey Conway/Harvard Staff Photographer Health Immune-system strategy used to treat cancer may help with Alzheimer’s Turning off checkpoint molecules freed microglia to attack plaques in brain, improved memory in mice Alvin Powell Harvard Staff Writer April 18, 2025 7 min read A new study raises the odds that a strategy already successful against some cancers may be deployed …
European Regulators Ok Alzheimer’s Treatment Leqembi After Initial Doubts
HYANNIS – European regulators have finally approved the Alzheimer’s treatment Leqembi after an advisory committee initially rejected the drug last summer and then reconsidered it. The infused treatment from Japanese drugmaker Eisai and Biogen received approval for patients in early stages of the fatal, mind-robbing disease. The decision applies to all 27 members of the […] The post European Regulators Ok Alzheimer’s Treatment Leqembi After Initi…
Coverage Details
Bias Distribution
- 44% of the sources lean Left
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage